PosterSessionOnline

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 21st World Congress on Gastrointestinal Cancer

3-6 July 2019 Barcelona

N. Poster

Poster title

Applicant name

Status


1-SO	Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer.	Shigenori Kadowaki	Received

1-PD	Analysis of patient screening in the phase III, international, randomized, open-label APACT trial	Michele Reni	Received

2-PD	CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial	SOMNATH MUKHERJEE	Received

2-SO	Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-nave advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)	Ian Chau	Received

3-PD	IDENTIFICATION OF A NANOSTRING SIGNATURE THAT DIFFERENTIATES EARLY PANCREATIC CANCERS ACCORDING TO STROMAL COMPOSITION AND PREDICTS CLINICAL OUTCOME	Chiara Braconi	Received

3-P	Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics	Margarita Kruchinina	Received

3-LBA	A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)	Yuko Hirano	Received

4-PD	Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC	Umberto Peretti	Received

4-P	Nine years of epidemiological changes of gastrointestinal cancer in Egypt	Rasha Aboelhassan	Received

4-O	Applied Precision Cancer Medicine in advanced Biliary Tract Cancer	Hossein Taghizadeh	Received

5-SO	A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer	Zev Wainberg	Received

5-PD	Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study	Eva Hortas	Received

5-P	Increased FLVCR1 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma	Suna Zhou	Received

6-P	miR-381-3p inhibits migration and invasion in ESCC through downregulated FLVCR1	wenguang ye	Received

6-SO	Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers	Omar Vivar	Received

6-PD	A predictive model for endoscopic ultrasonography accuracy of invasion depth in early gastric cancer	Jun Chul Park	Received

7-PD	Surgical Indication for advanced gallbladder cancer considering the optimal preoperative carbohydrate antigen 19-9 cut-off value	Eva Hortas	Received

7-O	ZEBRA: An ACCRU/IRCI Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small Bowel Adenocarcinoma (SBA)	Katrina Pedersen	Received

7-P	Rectal cancer in Albania: treatment outcome and prognostic factors of disease progression.	Elvisa Kozma	Received

7-LBA	Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC	Carlotta Antoniotti	Received

8-PD	Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers	Aparna Parikh	Received

9-P	Prognostic factors of untreated hepatocellular carcinoma on cirrhosis	STOIAN MARILENA	Received

9-PD	Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC	Eva Hortas	Received

10-O	VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer (EPOC 1504)	Hideaki Bando	Received

10-SO	Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.	Isabelle Ahrens-Fath	Received

10-PD	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study	Andrea Casadei Gardini	Received

10-P	GLOMERULAR FILTRATION RATE TO LIVER TRANSPLANTATION	STOIAN MARILENA	Received

11-PD	Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis	Ismael Ghanem	Received

12-P	Weighted gene co-expression networks explored MiR-92b Implicated In esophageal squamous cell cancer	Wanpeng Wang	Received

12-PD	Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort	Erik Osterman	Received

13-P	Surgical and combined treatment for patients with cholangiocarcinoma: the experience of FSBI	Aleksandr Polyakov	Received

13-PD	RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)	Yu Sunakawa	Received

13-O	Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies	Gemma Zucchelli	Received

14-P	Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life	Shuji Hiramoto	Received

15-P	Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy	Shuji Hiramoto	Received

15-PD	Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies	Daniele Rossini	Received

16-P	Long-course chemoradiation in carcinoma rectum; is it really worth it? Perspectives from a developing nation	DEEP CHAKRABARTI	Received

16-O	Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer	Victoria Raymond	Received

16-PD	Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study	Alessandra Raimondi	Received

17-PD	APC I1307K and risk of colorectal neoplasia in humans and mice	Stephen Gruber	Received

17-O	SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer	Jun Watanabe	Received

18-PD	Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer	KO Lam	Received

18-P	Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer	Youn Young Park	Received

18-O	Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study	Elizabeth Alwers	Received

19-PD	Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS	Claudia Cardone	Received

19-P	Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer	lucheng Zhu	Received

20-P	Surprisingly high prevalence of DPYD gene mutation in UK regional trust: implications for treatment	Samantha Kestenbaum	Received

20-PD	Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC)	Rahul Das	Received

20-O	Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy	Karen Gambaro	Received

21-PD	Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies	Eva Hortas	Received

21-P	Efficient treatment policies and its impact on the economic burden for CRC in low-middle income countries: the Egypt Case	Abdalla Abotaleb	Received

22-PD	PARP-ness in Metastatic Colorectal Cancer	Gianluca Mauri	Received

22-P	Which patients on chemotherapy for colorectal cancer should be anticoagulated?	Samantha Forner	Received

22-O	Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)	Donna Stefanoni	Received

23-PD	Survey on the Unmet Needs of Patients Living with mCRC Learnings from an International Study	Zorana Maravic	Received

24-PD	Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS	Sarah Novack	Received

25-PD	Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine	Claire Palles	Received

25-P	Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers	Gemma Bruera	Received

25-O	A randomized, multicenter, phase II trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients	filippo pietrantonio	Received

26-O	Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)	Inma Ruiz de Mena	Received

26-PD	Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113)	Ralf Hofheinz	Received

27-PD	Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis	Daniele Rossini	Received

27-P	Multidirectional colonoscopy quality improvement increases adenoma detection rate: results of the Seoul national university hospital healthcare system Gangnam center colonoscopy quality upgrade project (Gangnam-CUP)	Ji Yeon Seo	Received

28-PD	Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study.	Pia Osterlund	Received

29-P	Impact on survival of local complications in Pancreatic Cancer: experience at the Ramón y Cajal University Hospital (HURyC)	Juan Jose Serrano Domingo	Received

29-PD	Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer	OPEN Health Medical Communications	Received

30-PD	Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC)	Michael Geissler	Received

30-P	Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma	Hongjie Chen	Received

31-PD	Immune signatures identify three immune clusters in mCRC, with potential clinical implications	Leire Pedrosa	Received

31-P	Low level of centromere-associated protein E promotes growth of hepatocellular carcinoma and is associated with adverse clinical features	Yiguang Lin	Received

32-PD	Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait	Philippe Bulens	Received

32-P	Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer.	Letizia Deantonio	Received

33-PD	A prospective cohort study on the effect of radiotherapy for rectal cancer on female sexual function	Annika Svanstrm Rjvall	Received

34-PD	Clinical outcomes of rectal neuroendocrine tumors less than 20 mm: a single institutional analysis of 371 patients	Eva Hortas	Received

34-P	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer	Alison Sinclair	Received

35-P	Prognosis of gastric dysplasia according to mucin phenotype after complete resection with endoscopic procedures	Jin-Oh Kim	Received

36-P	Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer	JOLANTA ZOK	Received

37-P	Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities.	Juan Luis Sanz	Received

39-P	ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: results of a prospective single centre clinical utility study (PRECISE STUDY)	Thomas Starkey	Received

40-P	Cost of metastatic colorectal cancer drugs per month of life gained in Spain	silvina grasso	Received

41-P	Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients	Amer Radwi	Received

43-P	Scope position is a determining factor for diagnostic performance of EUS-FNA for mass lesions in the pancreas head and uncinate process	Nam Hee Kim	Received

46-P	Expression pattern of death receptors FasR and DR3 on NK and T cells defines the complexity of tumor-immune system interplay in esophageal cancer	Martin Snajdauf	Received

50-P	The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation.	Amy Case	Received

51-P	Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer	Vasileios Angelis	Received

53-P	Neoadjuvant rectal cancer (NAR) score as a prognostic factor in locally advanced rectal cancer patients in Assiut university hospital clinical oncology department	Mariam khalil	Received

54-P	Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST	Hiroshi Nakatsumi	Received

57-P	Interleukin-6 correlated with neutrophil-to-lymphocyte ratio in pancreatic cancer	Pop Vlad Vasile	Received

58-P	Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis.	Sarah Novack	Received

59-P	SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC).	Maria Loushin	Received

60-P	Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years	Eleni Xenophontos	Received

62-P	Predicting esophageal cancer outcome with positron emission tomography using deep convolutional neural network	Po-Kuei Hsu	Received

63-P	ROLE OF MAINTENANCE GEMCITABINE IN ADVANCED/METASTATIC CARCINOMA GALL BLADDER	MANISH SHARMA	Received

64-P	Self-expandable metal stent (SEMS) for esophageal-gastric junction versus pyloric area obstruction in advanced gastric cancer patients: a retrospective, comparative, single-center study	Hee Seok Moon	Received

65-P	A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study	Junichi Nakazawa	Received

66-P	Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role	Gonalo Nogueira-Costa	Received

69-P	Acute pancreatitis after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in an ongoing phase 1 study for peritoneal metastasis	Guowei Kim	Received

70-P	Esophageal cancer: 5 years of experience in a Mexican oncology reference center.	Carlos Eduardo Salazar-Mejía	Received

72-P	Effects of natural substances from Boswellia sacra and Nerium oleander (breastin) in colon and pancreatic cancer	PANAGIOTIS PARSONIDIS	Received

73-P	Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies	Gerardo Rosati	Received

74-P	A three-year study of epidemiological trends of gastrointestinal cancers in a Haitian cancer program	Doukens Patrick Gilbert	Received

75-P	SBRT in primary and metastatic liver disease: analysis after implementation in our center	Carolina De la Pinta	Received

76-P	Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features	Chinock Cheong	Received

78-P	Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer	Ivica Zarev	Received

80-P	Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase II trial (PRODIGE 58 UCGI 35 REGIRI)	Laure Monard	Received

82-P	Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting	Yifu He	Received

83-P	FLOT- or CROSS-protocol treatment in advanced adenocarcinoma of the esophagus: a retrospective single-center analysis	Jonas Herzberg	Received

85-P	Rectal adenocarcinoma: clinical predictive factors for tumor response after chemoradiotherapy	Carolina De la Pinta	Received

86-P	EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment	Merissa Lee	Received

88-P	Radiology-guided oesophageal stenting for the palliation of dysphagia: a single center experience	Rajarshi Roy	Received

89-P	FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial	Yara Torres	Received

92-P	Impact on survival of adjuvant chemotherapy following chemo-radiotherapy and surgery in locally advanced, non-metastatic rectal adenocarcinoma: a retrospective analysis among 331 patients	Marion SONDAG	Received

93-P	Male gender and bone metastases linked to inferior survival in advanced biliary tract cancer	Felipe Oliveira	Received

95-P	Gastroenteropancreatic neuroendocrine neoplasia G3 according to 2017 WHO classification: a comprehensive clinicopathological characterization including mismatch repair proteins and PDL1 expression in a large cohort of patients	Julieta Grasselli	Received

99-P	Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients	Emmanuelle SAMALIN	Received

100-P	Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience	Michael Tilby	Received

101-P	A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy	Alessandro Parisi	Received

102-P	Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at a dose of 130mg/m2 (nacG-SOX130) in clinical(c)Stage III gastric cancer.	Sayuri Konishi	Received

103-P	Prognostic implications of free cancer cells in gastric juice in gastric cancer patients who underwent surgery: a prospective cohort study	Dai Manaka	Received

104-P	Potent anticolorectal cancer activity of 5-fluorouracil and laccaic acid combination via modulation of epigenetic regulation	Riya Gupta	Received

108-P	Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018	Pasquale Lombardi	Received

112-P	A retrospective study on treatment outcomes for patients with high grade neuroendocrine colorectal carcinoma.	PAVLOS PISKILIDIS	Received

114-P	Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol	HIROAKI TANIOKA	Received

115-P	The onset of grade = 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil	Jacopo Giuliani	Received

116-P	GRADE evaluation of the COLOFOL randomized clinical trial	Eduardo Ceballos	Received

117-P	Stage IIa colon cancer: adjuvant chemotherapy in real life	Renato Cunha	Received

123-P	A Retrospective Qualitative Pilot Study Incorporating Patient Personal Life Aspects upon Admission to Palliative Care: What should we know about patients to give them the best care possible?	Anna Kitta	Received

124-P	Definitive chemoradiotherapy in oesophageal cancer: Treatment outcomes from a regional cancer centre	Mohammed Abdul-Latif	Received

125-P	Total neoadjuvant treatment of ugly rectal cancers in Slovenia	Vaneja Velenik	Received

126-P	The management of pancreatic adenocarcinoma in a hospitalized-based population (2015-2019)	aicha bengueddach	Received

128-P	Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.	Michele Ghidini	Received

129-P	Expression of female sex hormone receptors, connective tissue growth factor, and HER2 in gallbladder cancer and adjacent normal tissue	RENATA DUCHNOWSKA	Received

130-P	Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study	Mikhail Fedyanin	Received

132-P	A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism	hongyan yu	Received

133-P	A randomized, multicenter, open-label controlled phase II trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer	Peter Morsing	Received

134-P	Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study	Michele Reni	Received

136-P	Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types	Ralf Hofheinz	Received

137-P	Circulating T cell subsets differ in PDAC patients at initial diagnosis and after two months of treatment: a single institution prospective study	Skaiste Tulyte	Received

138-P	Alcohol consumption and tobacco smoking and ed gastrointestinal cancers morbidity rates in Poland	Miroslaw Jarosz	Received

139-P	Chemotherapy Rechallenge or Reintroduction (CTr/r), Regorafenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients: a PROpensity ScorE analysis of tReatment beyond the second liNe (PROSERpINa Study).	Maria Alessandra Calegari	Received

140-P	Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib	VINCENZO RICCI	Received

142-P	Sunitinib rechallenge in pancreatic neuroendocrine tumors	Vasiliki Michalaki	Received

143-P	Gastric cancer: system approach	Oleg Kshivets	Received

144-P	Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III	German Calderillo	Received

145-P	Gastric cancer in young Latin women: bad prognostic factors and outcomes.	German Calderillo	Received

147-P	Surgery specialization as a prognostic factor in colon cancer	German Calderillo	Received

149-P	High rates of hepatocellular carcinoma within two years of starting treatment for chronic hepatitis C with direct antiviral agents but not with PEG-interferon/ Ribavirin (HORRID Study)	Alexander Siebenhuener	Received

150-P	Perioperative FLOT experience: pathological regression and toxicity	Adrián Sánchez	Received

154-P	Correlation between neutrophil/lymphocyte ratio and postoperative infectious complications after pancreatoduodenectomy for carcinoma of the pancreas head	Lucia Romano	Received

156-P	Treatment for esophageal and esophagogastric junction cancer with radical radiotherapy: a single-institution cohort study	Vesna Bisof	Received

157-P	Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen.	Nieves Martinez-Lago	Received

158-P	Patient understanding of the aim and duration of treatment during the consent process	Gireesh Kumaran	Received

159-P	Patterns and predictors of relapse following radical chemoradiotherapy delivered using intensity-modulated radiotherapy with a simultaneous integrated boost in anal squamous cell carcinoma.	Rebecca Muirhead	Received

160-P	Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours	giulia arrivi	Received

162-P	Dose-escalated intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost (SIB) in rectal cancer	Rebecca Muirhead	Received

163-P	Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis	Ismael Ghanem	Received

166-P	Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX	Muhammad Bilal Razzaq	Received

168-P	Maximum tolerated radiation dose for unresectable thoracic esophageal squamous cell carcinoma: both acute and late toxicities matter	WEN YU	Received

169-P	Apatinib as non-first-line treatment in patients with advanced cholangiocarcinoma.	Jianzhen Lin	Received

170-P	Nutritional index differential as a prognostic factor for recurrence in patients with locally advanced rectal cancer	Ramos Maritza	Received

174-P	Proposal of optimal cut-off of preoperative serum tumor marker levels to predict postoperative recurrences of gastric cancer	Bin Sato	Received

175-P	The optimal time interval between self-expandable metallic stent placement and elective operation in patients with obstructive colon cancers: a multicenter retrospective analysis.	BONG-HYEON KYE	Received

176-P	Multicenter phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502)	Tetsuhito Muranaka	Received

178-P	A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients	Vincenzo Formica	Received

179-P	Retrospective analysis of 18 cases of gastric cancer with peritoneal metastases resulting in successful conversion surgery	Rio Honma	Received

180-P	A phase II study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403)	Naotoshi Sugimoto	Received

181-P	Efficacy of surgical resection in patients with recurrent tumor of intrahepatic cholangiocarcinoma	Junichi Arita	Received

182-P	Clinical importance of colonoscopy in patients with gastric cancer	Hee chan Yang	Received

183-P	Legumain is a predictive effector of peritoneal metastasis for diffuse gastric cancer patients	Yan Wang	Received

184-P	Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland	Miroslaw Jarosz	Received

185-P	Is intra-arterial hepatic chemotherapy painful?	Fouad Kerbage	Received

186-P	Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers	Andrea Mafficini	Received

188-P	Hepatic sinusoidal obstruction syndrome (HSOS) in cStage III gastric cancer patients undergoing neoadjuvant chemotherapy with oxaliplatin: a retrospective cohort study	Kiyotaka Kawaguchi	Received

191-P	Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)	Jorge Aparicio	Received

192-P	Complete peritonectomy versus ive peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes	ASHWIN KR	Received

193-P	FOLFIRINOX after first-line gemcitabine-based chemotherapy in metastatic pancreatic cancer: a mono-institutional experience	FRANCESCA FOSCHINI	Received

194-P	Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences	SÍlvia Duarte	Received

195-P	Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland	Miroslaw Jarosz	Received

198-P	Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy	ASHWIN KR	Received

199-P	Role of robotic surgery for rectal cancer: short-term, functional, and oncological outcomes for 150 consecutive patients	ASHWIN KR	Received

200-P	Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer	ASHWIN KR	Received

201-P	Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery	Michael Davidson	Received

203-P	The role of combined treatment of metastatic colorectal cancer in patients with liver metastases	Danila Gridnev	Received

204-P	Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer	Junghoon Bae	Received

205-P	Hepatocellular carcinoma: characteristics, outcomes, and prognostic fators	Adriana Novais Lopes Monteiro Soares	Received

206-P	Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab	Zoubida Behourah	Received

207-P	Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing	Lucia Ceniceros	Received

208-P	Phase II study in progress to verify improved response with mFOLFOX6 after exposure to an immune checkpoint inhibitor in advanced gastric cancer	Ahn Ann	Received

209-P	Sorafenib in patients with hepatocellular carcinoma: 10 years of real life	Giulia Rovesti	Received

210-P	Cytosponge for post-chemoradiation surveillance of oesophageal cancer: a feasibility study	SOMNATH MUKHERJEE	Received

211-P	A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel	Cristina Morelli	Received

213-P	CA19-9 decrease and predictive value for response in patients with metastatic pancreatic cancer treated with FOLFIRINOX	José Francisco Rodríguez Hernández	Received

214-P	Does PICC side matter? The experience at our hospital	Ana Gil Torralvo	Received

215-P	Recurrence rate in colorectal adenocarcinoma patients receiving adjuvant capecitabine monotherapy: do the number of chemotherapy cycles and relative dose intensity of the drug play a role?	Joseph Sgouros	Received

216-P	Neo-adjuvant Chemo-Radiation for Resectable Esophageal Carcinoma is Oral Capecitabine Non-Inferior to Paclitaxel Carboplatin Combination?	ALOKE GHOSH DASTIDAR	Received

218-P	L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease	Athanasios Tampakis	Received

219-P	Is there any affordable and reliable score in local gastric cancer?	Antia Cousillas	Received

220-P	Perioperative chemotherapy with FLOT vs other regimens for resectable gastric cancer	Tamar Esakia	Received

221-P	Locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients under 65 years with good performance status (PS) at Ramón y Cajal University Hospital in Madrid	Juan Jose Serrano Domingo	Received

222-P	Patient-reported outcomes including LARS score and quality of life one year after chemoradiotherapy for anal cancer	Karen-Lise Garm Spindler	Received

223-P	Quality of life and preoperative chemotherapy in gastric cancer in Chile: results from the observational study of perioperative chemotherapy in gastric cancer (PRECISO)	Bettina Mller	Received

224-P	HEPANOVA phase 2 study design: Tumor Treating Fields concomitant with sorafenib for the treatment of advanced hepatocellular carcinoma	James Wallis	Received

226-P	Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer - Single-centre retrospective cohort analysis of 186 patients	Juraj Prejac	Received

227-P	Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution.	Alberto Sánchez-Camacho Mejias	Received

228-P	Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro	James Wallis	Received

229-P	The value of alfa-fetoprotein and neutrophil/lymphocyte ratio (NLR) in the prognosis of patients with hepatocellular carcinoma	Catarina Quintela	Received

230-P	EFFECTIVENESS OF CA 19.9 IN PREDICTING PROGNOSIS IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH NAB-PACLITAXEL PLUS GEMCITABINE	Stefano Mariani	Received

231-P	Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients	Pop Vlad Vasile	Received

232-P	RENCA MACROBEAD THERAPY (RMB): A BIOLOGICAL-SYSTEMS APPROACH TO METASTATIC COLORECTAL CANCER U.S. FDA BB-IND 10091	Angelica Nazarian	Received

233-P	Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experience	Ravi Paluri	Received

235-P	Induction Chemotherapy with Taxane versus Anthracycline-based Triplet for Locally Unresectable Nonmetastatic Gastric Cancer	Clara Borges	Received

236-P	Histological Patterns and Clinical Characteristics of Metastatic Gastric Adenocarcinoma, Single institutional Experience in The Eastern Province of Saudi Arabia	Nedal Bukhari	Received

237-P	Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?	Tomislav Omrcen	Received

238-P	Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy	Donna Stefanoni	Received

239-P	Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis	Rafael Carmo	Received

240-P	Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at ONeal Comprehensive Cancer Center	Ravi Paluri	Received

243-P	A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis	Aysegl Ilhan-Mutlu	Received

245-P	Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer	Ravi Paluri	Received

246-P	The importance of laterality in colorectal cancer predicting response to therapeutics retrospective study evaluating differences between right and left colon in stage IV colon cancer	Élia Cipriano	Received

247-P	SPLANCHNIC VEIN THROMBOSIS IN CHOLANGIOCARCINOMA. A RETROSPECTIVE OBSERVATIONAL STUDY. DONOSTIA UNIVERSITY HOSPITAL.	ANA LANDA MAGDALENA	Received

248-P	Futility and Utility of Two-stage Hepatectomy	Miguel Cunha	Received

250-P	The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows in vitro and in vivo efficacy in hepatocellular carcinoma	James Wallis	Received

251-P	FLOT versus ECF/ECX peri-operative regimens in real life setting for patients with resectable gastric adenocarcinoma	Joana Graa	Received

253-P	Age vs Performance Status - Which is worst for surgery outcome?	Edgar Amorim	Received

254-P	LIQUID BIOPSY FOR RAS MUTATIONAL STATUS ANALYSIS IN METASTATIC COLORECTAL CANCER	JOANA MARINHO	Received

255-P	Outcomes of treatment for non-metastatic rectal cancer; a ten year single institute experience at the Bank of Cyprus Oncology Centre (BOCOC)	Ifigenia Konstantinou	Received

256-P	Locally advanced unresectable and metastatic pancreatic cancer predictors of survival	Élia Cipriano	Received

258-P	Computational simulations to determine the effectiveness and thermal safety of tumor treating fields with delivery to the abdomen	James Wallis	Received

259-P	A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBP signaling suppression of COX-2 in liver cancer	Yiguang Lin	Received

260-P	PANOVA phase 3 study design: Tumor Treating Fields (150 kHz) in combination with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC)	James Wallis	Received

262-P	Percutaneous transhepatic biliary drainage in malignant biliary obstruction: complications and outcome	MANOJ KUMAR	Received

264-P	Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF- and IGF 1 signaling pathways	Yan Chen	Received

265-P	RETROPERITONEAL LYMPH NODE METASTASES AS A PROGNOSIS FACTOR IN OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER	German Calderillo	Received

266-P	Metastatic pancreatic cancer: Characteristics of long-term survivors	margaret mandelson	Received

267-P	Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer	Tatiana Titova	Received

268-P	Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer	Anup Kasi	Received

269-P	PIPAC PACLITAXEL: A SYSTEMATIC AND PERITONEAL TISSUE PHARMACOKINETIC STUDY IN SWINE	Hon Lyn Tan	Received

271-P	Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience	Anup Kasi	Received

272-P	Is the gastroenterologist really necessary in the operating room? Intraoperative rectosigmoidoscopy: how we do it.	Edgar Amorim	Received

274-P	A MULTICENTER SPANISH RETROSPECTIVE STUDY OF PLATINUM-BASED CHEMOTHERAPY SENSITIVITY IN THE FIRST LINE SETTING AFTER RELAPSE FROM PERIOPERATIVE PLATINUM BASED CHEMOTHERAPY IN GASTRIC CANCER	Luis Paul Del Carpio Huerta	Received

275-P	Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs)	Massimiliano Salati	Received

277-P	Socioeconomic and Administrative Factors Associated with Health&8209;care Delay and Treatment of Esophageal and Gastric Carcinoma: Experience at a Tertiary Care Centre in a Developing Country	SYED ADIL HASSAN	Received

279-P	Characterization of mismatch repair deficiency in biliary tract cancer	Caterina Vivaldi	Received

281-P	EFFICACY OF A THERAPEUTIC EXERCISE PROGRAM ON AUTONOMIC NERVOUS SYSTEM FUNCTION, CARDIAC FUNCTION AND FUNCTIONAL CAPACITY IN COLORECTAL CANCER SURVIVORS: A RANDOMIZED CONTROLLED PILOT STUDY	Julia Ruiz-Vozmediano	Received

283-P	Predictors of Oxaliplatin-Induced Hepatotoxicity: Increase in Spleen Volume or Liver Fibrosis and Steatosis?	Malek Kreidieh	Received

285-P	The role of active nutritional intervention in patients receiving chemoradiation (CRT) for oesophageal cancer	Rob Owens	Received

286-P	The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with FIRST-LINE NAB-PACLITAXEL AND GEMCITABINE: POST-HOC ANALYSIS OF an Austrian multicenter, non-interventional study	Jakob M. Riedl	Received

288-P	The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA)	Debora Basile	Received

289-P	Incidence and severity of cancer-related fatigue in gastric cancer patients	Bogdan Gafton	Received

290-P	Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes	Kunal Kadakia	Received

291-P	NRG1-fusion positive gastrointestinal tumours: Afatinib as a novel potential treatment option	Benjamin Weinberg	Received

293-P	EVALUATION OF NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER BEFORE AND AFTER NEOADJUVANT RADIOCHEMOTHERAPY BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCLE)	Renato Cannizzaro	Received

294-P	Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis	Lisa Salvatore	Received

296-P	Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience	Andrea Pretta	Received

297-P	Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease	Maria Radanova	Received

298-P	Directed differentiation of human pluripotent stem cells into hepatic tissue with gallbladder and bile ducts organoids in vitro	Fenfang Wu	Received

299-P	Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients	Silvia Catanese	Received

300-P	Pancreatic Cancer resection in elderly patients: Analysis of outcomes	MARIANA GARCÍA VIROSTA	Received

302-P	Prospective Evaluation of FOLFIRINOX in Neo-adjuvant Treatment of Gastro-Oesophageal Junction Carcinomas	Nicholas Travers	Received

303-P	Third-line re-treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel	Adarsh Das	Received

304-P	Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less	Adarsh Das	Received

305-P	K-Ras mutation in liquid biopsy and tumor tissue correlation in patients with pancreatic cancer	EDUARDO JOSÉ PERDOMO ZALDIVAR	Received

306-P	Anal cancer outcomes and human immunodeficiency virus: a single-center experience	Carmen García Durán	Received

307-P	Epidemiology, treatment and prognostic factors of colorectal cancers in Tunisia: compliance with recommendations and therapeutic results	Sarra Karrit	Received

308-P	Role of TILS in predicting evolution of metastatic colorectal cancer	sonia ben nasr	Received

310-P	Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma	Carles Fabregat Franco	Received

314-P	Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)?	ROXANA REYES	Received

315-P	?Np73 and ?133p53 in liquid biopsy as early diagnostic markers for colorectal cancer	Javier Rodríguez-Cobos	Received

316-P	Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India.	Prabhat Bhargava	Received

317-P	Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study)	Maria Bensi	Received

319-P	Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer	Lorenzo Fornaro	Received

320-P	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: real-world data of 13 oncological centers in Portugal	Tiago Cruz Tomás	Received

321-P	Young Onset Rectal Cancer: a Therapeutic Challenge	Debapriya Mondal	Received

323-P	Is FNA always necessary in submucosal lesion miming GIST?	Renato Cannizzaro	Received

324-P	Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Experience	Rojymon Jacob	Received

326-P	CLINICAL PRACTICE USE OF LIQUID BIOPSY TO IDENTIFY RAS/BRAF MUTATIONAL STATUS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): A SINGLE INSTITUTION EXPERIENCE	Vincenzo De Falco	Received

327-P	Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction	OPEN HEALTH MEDICAL COMMUNICATIONS	Received

328-P	Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey	Zorana Maravic	Received

330-P	Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data	Pasquale Vitale	Received

331-P	Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study.	Tomomi Kashiwada	Received

332-P	A new prognostic score for biliary tract cancer: a multicenter experience	Pina Ziranu	Received

333-P	Early fluorescence detection of oropharengeal and esophageal cancer	Rasul Sadykov	Received

335-P	FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group).	Federico Longo Muñoz	Received

339-P	Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia	Imtinen Belaid	Received

341-P	Health disparities and gastric cancer survival in Cali, Colombia: a hospital-based study	Angela Zambrano	Received

344-P	Survival analysis of gastric cancer in a Hispanic population: 15-years of experience at a specialized cancer center	Angela Zambrano	Received

346-P	A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors	Ines Rego	Received

347-P	THE RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) UNDER IMATINIB MESYLATE TREATMENT	DIMITRIOS TZILVES	Received

348-P	Esophageal cancer: about 42 cases Experience of the medical oncology department of Hassan II University Hospital of Fez, Morocco	Nouiakh Lamyae	Received

350-P	Management of gallbladder cancer - EXPERIENCE OF MEDICAL ONCOLOGY DEPARTMENT ABOUT 140 CASES	Nouiakh Lamyae	Received

352-P	Prognostic Value, Clinicopathologic Features and Diagnostic Accuracy of Interleukin-8 in Colorectal Cancer: A prospective study in 60 patients in Tunisia.	Sarra Karrit	Received

353-P	Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX	Hanane Fatima Zahra Aliane	Received

354-P	Survival and prognostic factors of localized gastric carcinomas (about 50 cases). Experience of the medical oncology department of Hassan II University of Fez	hayat erraichi	Received

355-P	To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology	Pujarini Dash	Received

356-P	COLORECTAL CANCER IN YOUNG TUNISIAN PATIENTS: clinical, histopathological and RAS testing data	HAYFA GUETTITI TOUNSI	Received

357-P	The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer	Hanane Fatima Zahra Aliane	Received

362-P	Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study	Solene Doat	Received

364-P	High expression of oestrogen receptor beta correlates with anti-tumorigenic inflammatory proteins in colorectal cancer.	Geriolda Topi	Received

366-P	Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer	Enas Elkhouly	Received

367-P	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer	Joana Simes	Received

368-P	Chemoradiation and surgery versus chemoradiation followed by neoadjuvant chemotherapy and surgery in locally advanced rectal cancer: a retrospective analysis of a single center experience	Bárbara Lima	Received

369-P	Home chemotherapy in colorectal cancer: First experience in Argentina	guillermo streich	Received

370-P	Role of radiotherapy in local control of metastatic rectal cancer: a single-center experience	Ana Afonso	Received

371-P	Feasibility of modulated electro-hyperthermia as a concomitant boost to preoperative radiotherapy in locally advanced rectal cancer: A phase 2 trial	Seihwan You	Received

375-P	Palliative management of malignant biliary obstruction in patients with advanced biliary tract cancers	SOUMIA berrad	Received

376-P	Primary malignant tumors of the small intestine: clinical and therapeutic aspects	SOUMIA berrad	Received

381-P	The management of neuroendocrine gastroenteropancreatic tumors.	SOUMIA berrad	Received

382-P	Clinicopathologic feature of microsatellite stable early-onset colorectal cancer	Rumi Shin	Received

383-P	Survival and prognostic factors for stage II colon cancer	SOUMIA berrad	Received

384-P	Anal Carcinoma A comparative analysis of the standard treatment vs An hypofractionated schedule (the Tlalpan Regime) experience at the Instituto Nacional de Cancerología, México.	Jesús Zamora	Received

385-P	PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib	Long Pan	Received

389-P	Clinical Significance of BRAF Mutations in Colorectal Cancer: A Retrospective Study of One Institution in a real-life population.	Lidia Carnerero Córdoba	Received

392-P	Minimally invasive surgical approach for the treatment of esophageal cancer as a component of multimodal treatment	Yestay Abzalbek	Received

395-P	Expression of MMR in Women High Grade Carcinoma of Unknown Primary	Joni Howells	Received

398-P	The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital	Michael Davidson	Received

399-P	How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases	Syrine SGHAIER	Received

402-P	Incidence and mortality rates of cholangiocarcinoma in England	Tracey Genus	Received

ESMO 21st World Congress on Gastrointestinal Cancer

3-6 July 2019 Barcelona

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 06/07/2019 TO 03/07/2023

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.21wcgic.2019



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access